AVITA Medical, Inc. (RCEL): Results of Operations and Financial Condition
AVITA Medical, Inc. (RCEL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 AVITA Medical Reports Second Quarter Results, Raises 2026 Revenue Guidance, and Expects Fourth Quarter Cash Flow Breakeven VALENCIA, Calif., August 6, 2026 (GLOBE NEWSWIRE) — AVITA Medical ® , Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care comp
How this was made
The 30-second read
Why it matters
Traders can update RCEL valuation inputs immediately using the raised 2026 revenue range and the company’s stated expectation to reach cash-flow breakeven in Q4 2026. The CMS proposed 2027 Medicare payment updates for RECELL add a potential reimbursement tailwind, but it is not final.
Market read
This is a primary-source earnings and guidance update with explicit cash-flow breakeven timing and a US reimbursement policy catalyst for RECELL.
What to watch
Cash balance and net cash use remain meaningful (cash use improved but still negative), and the credit facility tranche depends on trailing-twelve-month net revenue thresholds, which could constrain upside if execution slips.
AVITA Medical Reports Second Quarter Results, Raises 2026 Revenue Guidance, and Expects Fourth Quarter Cash Flow Breakeven
Record revenue grew 18% year over year and 13% sequentially, gross margin expanded, operating expenses declined, net loss narrowed, and the Company raised full-year 2026 revenue guidance while expecting fourth-quarter cash flow breakeven.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Total revenueother | approximately $21.7 million | 13% | 18% |
| Gross profit marginother | 81.9% | – | an increase of 70 basis points year-over-year |
| RECELL-only gross marginother | 86.0% | – | – |
| Operating expensesother | $24.6 million | – | down 6% or $1.5 million |
| Net lossother | $7.7 million | – | – |
| Net loss per basic and diluted shareother | a loss of $0.25 per basic and diluted share | – | – |
| Net cash useother | approximately $3.2 million | – | – |
| Cash, cash equivalents, and marketable securitiesother | approximately $11.1 million | – | – |
| 2025 revenueother | $71.6 million | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| RECELLSequential growth was supported by increasing physician confidence following reimbursement stabilization and continued adoption of RECELL GO mini, which expanded utilization in smaller wounds. | $18.5 million | approximately 11% growth compared to Q1 2026 | – |
| CohealyxGrowth was supported by favorable interim clinical data from the Cohealyx I clinical study reported in April demonstrating a faster time to skin grafting readiness than leading competitive products. | $1.7 million | approximately 16% growth compared to Q1 2026 | – |
| PermeaDermPermeaDerm gained traction during the second quarter as an alternative to allograft to temporarily stabilize and protect the wound before definitive closure. | $0.6 million | approximately 40% growth compared to Q1 2026 | – |
| InternationalEstablished international markets continued to contribute consistent revenue. | $0.9 million | approximately 26% growth compared to Q1 2026 | – |
full-year 2026 outlook
- Revenue$86 million to $89 million
- Noteyear-over-year growth in the range of 20% to 24%
- Noteexpects to achieve cash flow breakeven in the fourth quarter of 2026
What drove it
- Total revenue growth was driven by continued execution across the commercial portfolio, led by RECELL and supported by Cohealyx and PermeaDerm.
- Gross profit margin reflected RECELL growth alongside expansion of the product portfolio.
- Operating expense reductions reflected cost optimization initiatives and commercial restructuring actions implemented in 2025.
- Sales and marketing expenses decreased by $0.7 million, and general and administrative expenses decreased by $0.7 million.
- Research and development expenses were flat with the prior-year period.
- Improved timely customer cash collections are expected to support the path to cash flow breakeven.
Concerns
- The Company reported a net loss of $7.7 million and expects cash flow breakeven only in the fourth quarter of 2026.
- The Company shares the average sales price for Cohealyx at 50% and for PermeaDerm at 60%, which it said inevitably results in an overall decrease in gross margin percentage.
- The proposed 2027 Medicare payment updates for RECELL remain subject to final CMS rules.
- Availability of the additional $10 million credit-facility tranche is contingent on achieving at least $85 million of trailing twelve-month net revenue in any month prior to March 31, 2027.
What to watch
- Execution toward full-year 2026 net revenue guidance of $86 million to $89 million.
- Achievement of expected cash flow breakeven in the fourth quarter of 2026.
- Presentation of PermeaDerm I study data in August.
- CMS final rules later this year and implementation effective January 1, 2027.
- Progress toward at least $85 million of trailing twelve-month net revenue needed for the additional credit-facility tranche.
Balance sheet and cash flow
- Net cash use improved to approximately $3.2 million, from $9.9 million in Q1 2026.
- Cash, cash equivalents, and marketable securities were approximately $11.1 million at the end of the quarter, compared with $14.3 million at the beginning of the quarter.
- Under the existing credit facility, an additional tranche of $10 million remains available upon achieving at least $85 million of trailing twelve-month net revenue in any month prior to March 31, 2027.
Analysis
AVITA reported record second-quarter revenue of approximately $21.7 million, up 18% from the prior-year period and 13% sequentially. RECELL remained the principal commercial contributor at $18.5 million, while Cohealyx, PermeaDerm, and international revenue each posted sequential growth. Management attributed RECELL growth to increasing physician confidence following reimbursement stabilization and continued RECELL GO mini adoption in smaller wounds.
The quarter showed favorable reported margin and cost trends. Gross profit margin was 81.9%, compared with 81.2% in the prior-year period, and RECELL-only gross margin was 86.0%. The Company noted that its average-sales-price sharing arrangements for Cohealyx and PermeaDerm, at 50% and 60%, respectively, inevitably reduce the overall gross-margin percentage as those products expand. This makes portfolio mix an important factor alongside revenue growth.
Operating expenses declined 6%, or $1.5 million, to $24.6 million, reflecting cost optimization and commercial restructuring actions implemented in 2025. Sales and marketing expenses decreased by $0.7 million, general and administrative expenses decreased by $0.7 million, and research and development expenses were flat with the prior-year period. The lower expense base, together with revenue growth, coincided with a narrower net loss of $7.7 million, versus $9.9 million in the prior-year period.
Cash use also improved. Net cash use was approximately $3.2 million, compared with $9.9 million in Q1 2026, while cash, cash equivalents, and marketable securities were approximately $11.1 million at quarter-end compared with $14.3 million at the beginning of the quarter. Management expects improved timely customer cash collections, high gross margins, and expense management to support cash flow breakeven and cash generation in the fourth quarter of 2026. The Company also has a conditional additional $10 million credit-facility tranche tied to at least $85 million of trailing twelve-month net revenue before March 31, 2027.
Management raised full-year 2026 revenue guidance to $86 million to $89 million from $80 million to $85 million and reiterated an expected path to fourth-quarter cash flow breakeven. The Company cited proposed CMS calendar-year 2027 updates that could establish national physician payment for RECELL and increase hospital outpatient and ambulatory surgical center facility payment rates if finalized. Near-term operating milestones include the expected August presentation of PermeaDerm I study data and CMS final rules expected later this year.
Management, verbatim
We delivered a strong second quarter, with revenue growing 18% year-over-year and 13% sequentially. As AVITA continues to expand utilization in the U.S. and build its presence in key international markets, our results reflect the strength of both our acute wound care portfolio and our commercial execution, led by RECELL and supported by Cohealyx and PermeaDerm.
Cary Vance, President and Chief Executive Officer of AVITA Medical
During the second quarter, we maintained a disciplined approach to operating expenses while delivering record revenue and, as expected, a further reduction in net use of cash. As the business continues to scale, supported by sustained high gross margins, operating expense management, and improved timely customer cash collections, we expect to reach cash flow breakeven and to start generating cash in the fourth quarter of 2026.
David O'Toole, Chief Financial Officer
Not in the filing
stated, not guessed- GAAP and non-GAAP basis labels or reconciliations for reported revenue, gross margin, operating expenses, net loss, and loss per share
- Gross profit in dollars
- Operating income or operating loss
- Operating cash flow
- Free cash flow
- Debt balance
- Tax expense and tax rate
- Diluted weighted-average shares outstanding
- Share repurchases
- Dividends
- Full-year 2026 guidance for gross margin, operating expenses, tax rate, earnings, or earnings per share
- Prior-quarter total revenue amount
- Prior-year revenue comparisons for RECELL, Cohealyx, PermeaDerm, and International
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
AVITA Medical filed an 8-K with Exhibit 99.1 reporting Q2 2026 financial results and updating full-year guidance, alongside commentary on RECELL reimbursement developments.
Ticker impact
AVITA Medical reports Q2 results, raises 2026 revenue guidance to $86M-$89M, and expects cash-flow breakeven in Q4 2026.
Near-term bias higher as traders reprice FY revenue expectations and the probability/timing of cash-flow breakeven; follow-through depends on how the market values the CMS proposal and upcoming PermeaDerm I data.
The filing includes fresh, decision-relevant numbers (Q2 revenue growth, raised full-year guidance range, and explicit Q4 cash-flow breakeven expectation) plus a concrete policy catalyst (CMS proposed 2027 Medicare payment updates for RECELL).
Market effects
Reinforces investor appetite for acute wound care and regenerative medicine names when reimbursement frameworks appear to be improving.
Limited direct regional read-through; international revenue growth is mentioned but the key policy catalyst is US Medicare.
Modest, since the reimbursement proposal is US-specific, though it can affect global commercialization expectations for RECELL.
Counterpoint
CMS rules are only proposed, and PermeaDerm I data is still pending; the guidance raise may already reflect known momentum, limiting upside beyond breakeven narrative.
Key entities
- issuerAVITA Medical, Inc.
NASDAQ-listed therapeutic acute wound care company reporting Q2 results and raising 2026 revenue guidance.
- productRECELL
AVITA’s skin cell suspension autograft product, the main revenue driver discussed in the filing.
- regulatorCenters for Medicare & Medicaid Services (CMS)
Proposed 2027 Medicare payment updates for RECELL-related procedures, if adopted.
- productPermeaDerm
Wound temporizer product; PermeaDerm I study data expected in August per the filing.
